Pharmaceutical nanocrystals

Current Opinion in Chemical Engineering

Volumn 1, Issue 2, 2012, Pages 102-107

  Wang, George Duo ^a   Mallet, Franck P ^b   Ricard, Francois ^b   Heng, Jerry Y Y ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; DISSOLUTION; ENVIRONMENTAL IMPACT; NANOCRYSTALS; NANOPARTICLES;

DOSAGE FORMS; DRUG MOLECULES; ENHANCED PERMEABILITY; MANUFACTURING PROCESS; SUBMICRON; TARGETED DELIVERY; TECHNICAL CHALLENGES;

DRUG DELIVERY;

EID: 84863986756     PISSN: None     EISSN: 22113398     Source Type: Journal    
DOI: 10.1016/j.coche.2011.12.001     Document Type: Review

References (61)

1. Farokhzad OC, Langer R: Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20. This is an excellent concise overview of the use of nanotechnology in pharmaceutical development by one of the foremost experts in drug delivery and pharmaceutical nanotechnology.
2. Irvine DJ: Drug delivery: one nanoparticle, one kill. Nat Mater 2011, 10:342-343.
3. Cormode DP, SkajaaT, Fayad ZA, MulderWJM: Nanotechnology in medical imaging probe design and applications. Arterioscler Thromb Vasc Biol 2009, 29:992-1000.
4. Shi J, Votruba AR, Farokhzad OC, Langer R: Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010, 10:3223-3230.
5. Joachim C: To be nano or not to be nano? Nat Mater 2005, 4:107-109. (Pubitemid 40178703)
6. BSI: Nanoparticles. Vocabulary. United Kingdom: British Standards Institution; 2011:. 36.
7. Allen TM, Cullis PR: Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822. This review is slightly dated but provides a fantastic detailed history of the application of nanoparticles in pharmaceuticals. (Pubitemid 38374867)
8. Dusastre V: Nanomedicine: a matter of rhetoric? Nat Mater 2006, 5:243. This short editorial summarizes the economic impact of nanotechnology on current pharmaceutical development and the growing investment from government and private sector.
9. Eifler AC, Thaxton CS: Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. In Biomedical Nanotechnology, vol 726. Edited by Hurst SJ. Humana Press; 2011:325-338.
10. Korkin A, Kristic PS, Wells JC: Nanotechnology for Electronics, Photonics, and Renewable Energy. Springer; 2010.
11. Nalwa HS: Handbook of Nanostructured Materials and Nanotechnology. Academic Press; 2000.
12. Sotiriou GA, Pratsinis SE: Engineering nanosilver as an antibacterial, biosensor and bioimaging material. Curr Opin Chem Eng 2011, 1:3-10.
13. Hua Chun Z: Preparation and integration of nanostructured titanium dioxide. Curr Opin Chem Eng 2011, 1:11-17.
14. Amidon GL, Lennernäs H, Shah VP, Crison JR: Atheoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995, 12:413-420.
15. Blagden N, de Matas M, Gavan PT, York P: Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 2007, 59:617-630. An excellent review discussing various crystal engineering approaches, including theory and concept, benefits and disadvantages of the different methods, for poorly soluble drugs. (Pubitemid 47285407)
16. Huang L-F, Tong W-Q: Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev 2004, 56:321-334. (Pubitemid 38201428)
17. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB: Oral bioayailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm 2006, 317:82-89. (Pubitemid 43866342)
18. Muller RH, Keck CM: Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004, 113:151-170. (Pubitemid 39237077)
19. Tamai I, Tsuji A: Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000,89:1371-1388.
20. Corot C, Robert P, Idee J-M, Port M: Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006, 58:1471-1504. (Pubitemid 44820503)
21. LipinskiC: Poor aqueous solubility - an industry wide problem in drug discovery. Am Pharm Rev 2002, 5:82-85.
22. Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, Rake J, Shaw JM, Pugh S, Polin L et al.: Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 1996, 13:272-278. (Pubitemid 26074194)
23. Müller RH, Peters K: Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm 1998, 160:229-237. (Pubitemid 28083096)
24. Rabinow BE: Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004, 3:785-796. (Pubitemid 39242830)
25. Gao L, Zhang D, Chen M: Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res 2008, 10:845-862.
26. Hu J, Johnston KP, Williams RO: Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm 2004, 30:233-245. (Pubitemid 38451748)
27. Peltonen L, Hirvonen J: Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol 2010, 62: 1569-1579.
28. Vehring R: Pharmaceutical particle engineering via spray drying. Pharm Res 2008, 25:999-1022. This expert review from Reinhard Vehing gives to the reader an in depth theoretical and experimental approaches to the particle engineering using spray drying. The literature review conducted by the author is complete with more than 400 references. This article needs to be studied "not only read" as it teaches a lot on the possibility of the technique.
29. Six K, Verreck G, Peeters J, Brewster M, Mooter GVd: Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci 2004, 93:124-131. (Pubitemid 38081820)
30. Lee J, Cheng Y: Critical freezing rate in freeze drying nanocrystal dispersions. J Control Release 2006, 111:185-192. (Pubitemid 43290007)
31. Jung J, Perrut M: Particle design using supercritical fluids: literature and patent survey. J Supercrit Fluids 2001,20:179-219. (Pubitemid 32607129)
32. Panagiotou T, Mesite SV, Fisher RJ: Production of norfloxacin nanosuspensions using microfluidics reaction technology through solvent/antisolvent crystallization. Ind Eng Chem Res 2009, 48:1761-1771.
33. Niwa T, Nakanishi Y, Danjo K: One-step preparation of pharmaceutical nanocrystals using ultra cryo-milling technique in liquid nitrogen. Eur J Pharm Sci 2010, 41:78-85.
34. Keck CM, Muller RH: Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006, 62:3-16. (Pubitemid 41736019)
35. Kesisoglou F, Panmai S, Wu Y: Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007, 59:631-644. This review discusses the need for nanosizing and includes fundamental principles, production and characterization of the nanoformulations, for both small molecule and biopharmaceuticals. (Pubitemid 47285408)
36. Beirowski J, Inghelbrecht S, Arien A, Gieseler H: Freeze-drying of nanosuspensions: 1. Freezing rate versus formulation design as critical factors to preserve the original particle size distribution. J Pharm Sci 2011, 100:1958-1968.
37. Holland SJ, Knight WA, Leonard GS: Wet milling process. US 2004/0089753 A1. United States; 2004:9.
38. Na GC, Stevens J, Yuan BO, Rajagopalan N: Physical stability of ethyl diatrizoate nanocrystalline suspension in steam sterilization. Pharm Res 1999, 16:569-574. (Pubitemid 29191304)
39. Junghanns J-UAH, Müuller RH: Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008, 3:295-310. Dr Müller from Free University of Berlin is one of the world's foremost experts on nanocrystals and nanosuspensions with over 300 publications relating to this field, and this is one of his most recent and easily accessible reviews. This and others by him and his group are must reads in order to gain an insight to this field of research.
40. Müller RH, Shegokar R, Gohla S, Keck CM: Nanocrystals: production, cellular drug delivery, current and future products. In Intracellular Delivery, vol 5. Edited by Prokop A. Netherlands: Springer; 2011:411-432.
41. Health and Safety Executive: Literature review - explosion hazards associated with nanopowders. Press Release March 2004.
42. Lee J: Drug nano- and microparticles processed into solid dosage forms: physical properties. J Pharm Sci 2003, 92:2057-2068. (Pubitemid 37175635)
43. Choi JY, Yoo JY, Kwak HS, Nam BU, Lee J: Role of polymeric stabilizers for drug nanocrystal dispersions. Curr Appl Phys 2005, 5:472-474. (Pubitemid 40714976)
44. Patravale VB, Date AA, Kulkarni RM: Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 2004, 56:827-840. (Pubitemid 38885975)
45. Dressman JB, Amidon GL, Reppas C, Shah VP: Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998, 15:11-22. (Pubitemid 28080861)
46. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K: Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm 2005, 299:167-177. (Pubitemid 40962418)
47. Mauludin R, Müller RH, Keck CM: Kinetic solubility and dissolution velocity of rutin nanocrystals. EurJ Pharm Sci 2009, 36:502-510.
48. Hancock BC, Parks M: What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 2000, 17: 397-404. (Pubitemid 30395293)
49. Hancock BC, Zografi G: Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997, 86:1-12.
50. Duchêne D, Ponchel G: Bioadhesion of solid oral dosage forms, why and how? Eur J Pharm Biopharm 1997, 44:15-23. (Pubitemid 28298771)
51. Otsuka H, Nagasaki Y, Kataoka K: PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2003, 55:403-419. (Pubitemid 36293792)
52. Merisko-Liversidge EM, Liversidge GG: Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 2008, 36:43-48.
53. Müller RH, Jacobs C, Kayser O: Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001, 47:3-19. Another very comprehensive review by Dr Muller from Free University of Berlin on nanocrystals and nanosuspensions. Like Ref. [39], this and others by him and his group are must reads in order to gain an insight to this field of research. (Pubitemid 32209229)
54. Filipe V, Hawe A, Jiskoot W: Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 2010, 27:796-810.
55. Swann MJ, Peel LL, Carrington S, Freeman NJ: Dual-polarization interferometry: an analytical technique to measure changes in protein structure in real time, to determine the stoichiometry of binding events, and to differentiate between specific and nonspecific interactions. Anal Biochem 2004, 329:190-198. (Pubitemid 38684155)
56. Heng JYY, Bismarck A, Lee AF, Wilson K, Williams DR: Anisotropic surface energetics and wettability of macroscopic form I paracetamol crystals. Langmuir 2006, 22:2760-2769.
57. Thielmann F, Burnett DJ, Heng JYY: Determination of the surface energy distributions of different processed lactose. Drug Dev Ind Pharm 2007, 33:1240-1253. (Pubitemid 350208733)
58. Ho R, Wilson DA, Heng JYY: Crystal habits and the variation in surface energy heterogeneity. Cryst Growth Des 2009, 9: 4907-4911.
59. Ho R, Hinder SJ, Watts JF, Dilworth SE, Williams DR, Heng JYY: Determination of surface heterogeneity of D-mannitol by sessile drop contact angle and finite concentration inverse gas chromatography. Int J Pharm 2010, 387:79-86.
60. Jefferson AE, Williams DR, Heng JYY: Computing the surface energy distributions of heterogeneous crystalline powders. J Adhes Sci Technol 2011, 25:339-355.
61. Ho R, Muresan AS, Hebbink GA, Heng JYY: Influence of fines on the surface energy heterogeneity of lactose for pulmonary drug delivery. Int J Pharm 2010, 388:88-94. All books cited are appropriate starting points into understanding the vast field of nanotechnology, nanoparticles and more specifically nanocrystals and nanosuspensions with relation to development of pharmaceuticals.